42471-28-3

42471-28-3 structure

Name: Nimustine Hydrochloride
Chemical Name: nimustine
CAS Number: 42471-28-3
Molecular Formula: C₉H₁₃ClN₆O₂
Molecular Weight: 272.69200
Catalog: API Antineoplastic agents Alkylating agent
Create Date: 2018-06-09 02:57:06
Modify Date: 2024-01-02 09:53:15
Nimustine is a nitrosourea alkylating agent. Nimustine induces cell apoptosis, and activates DNA damage response and MAPK signaling. Nimustine shows anti-cancer effects, it can be used for the research of cancer[1][2].

Name	nimustine
Synonyms	EINECS 255-838-1 NIMUSTINE 1-(2-chloroethyl)-1-nitroso-3-[(2-methyl-4-aminopyrimidine-5-yl)methyl]urea 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1-(2-chloro-ethyl)-1-nitroso-urea MFCD01676942 Nimustina Nimustin Nimustinum [INN-Latin] 1-(2-chloro-ethyl)-3-(4-amino-2-methyl-5-pyrimidinyl)methyl-1-nitrosourea Nimustina [INN-Spanish] Nimustine [INN] Nimustinum

Description	Nimustine is a nitrosourea alkylating agent. Nimustine induces cell apoptosis, and activates DNA damage response and MAPK signaling. Nimustine shows anti-cancer effects, it can be used for the research of cancer[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	Nimustine (50 μM; 72-120 h) causes cell death by inducing cell apoptosis[1]. Nimustine (50 μM; 24-96 h) activates the DNA damage response pathway[1]. Nimustine (50 μM; 24-120 h) activates MAPK signaling in glioma cells[1]. Apoptosis Analysis[1] Cell Line: LN-229 cell line Concentration: 50 μM Incubation Time: 72-120 hours Result: Time-dependently induced apoptosis. Western Blot Analysis[1] Cell Line: LN-229 and glioma cell lines Concentration: 50 μM Incubation Time: 24-120 hours Result: Induced cleavage of caspase-8 and -9 and the effector caspase-3. Increased phosphorylation of ERK kinase and H2AX. Decreased phosphorylation of JNK
In Vivo	Nimustine (15 four times a week and 30 mg/kg twice with an interval of 2 weeks; i.v.) effectively inhibits tumor growth and the higher dose is more effective[2]. Animal Model: Female C3H/HeN mice with solid FM3A tumors[2] Dosage: 15 and 30 mg/kg Administration: Intravenous injection; 15 (4 times a week) and 30 mg/kg (twice with an interval of 2 weeks) Result: The intermittent large-dose injections resulted in better inhibition of tumor growth than did the fractionated small-dose injections.

CHEMICAL NAME :: Urea, N'-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chlo roethyl)-N-nitroso-

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 149,95,1985

42471-43-2

42471-28-3

Literature: Sankyo Company Limited Patent: US4003901 A1, 1977 ;

Precursor 1
42471-43-2
DownStream 0

HS Code	2933599090
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%